Premium
Initial experience with the intravascular contrast agent NC100150‐injection (Clariscan®) for breath‐hold and navigator‐gated magnetic resonance coronary artery imaging
Author(s) -
Bunce Nicholas H.,
Keegan Jennifer,
Gatehouse Peter D.,
Moon James C.C.,
Firmin David N.,
Hoffmann Volker,
Pennell Dudley J.
Publication year - 2002
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.10151
Subject(s) - medicine , magnetic resonance imaging , artery , contrast (vision) , radiology , image quality , coronary artery disease , coronary arteries , cardiology , artificial intelligence , computer science , image (mathematics)
Purpose To examine magnetic resonance coronary artery imaging after NC100150‐Injection. Materials and Methods Breath‐hold and navigator‐gated images were acquired in five patients. Results Breath‐hold image quality, coronary artery‐fat SDNR, and coronary artery SNR improved. Respiratory artifacts due to reduced liver signal intensity degraded navigator‐gated image quality. Conclusion NC100150‐Injection improves breath‐hold coronary artery imaging. Navigator‐gated acquisitions should use techniques that are insensitive to T2* effects. J. Magn. Reson. Imaging 2002;16:217–223. © 2002 Wiley‐Liss, Inc.